Cabaletta Bio Inc (CABA)
10.17
+0.24
(+2.42%)
USD |
NASDAQ |
May 31, 16:00
10.17
0.00 (0.00%)
After-Hours: 20:00
Cabaletta Bio Enterprise Value: 267.13M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 267.13M |
| May 30, 2024 | 255.54M |
| May 29, 2024 | 261.33M |
| May 28, 2024 | 291.27M |
| May 24, 2024 | 303.33M |
| May 23, 2024 | 317.33M |
| May 22, 2024 | 346.30M |
| May 21, 2024 | 364.65M |
| May 20, 2024 | 397.96M |
| May 17, 2024 | 372.37M |
| May 16, 2024 | 385.40M |
| May 15, 2024 | 388.78M |
| May 14, 2024 | 318.30M |
| May 13, 2024 | 319.75M |
| May 10, 2024 | 319.75M |
| May 09, 2024 | 365.76M |
| May 08, 2024 | 359.00M |
| May 07, 2024 | 390.85M |
| May 06, 2024 | 396.64M |
| May 03, 2024 | 373.96M |
| May 02, 2024 | 384.09M |
| May 01, 2024 | 374.93M |
| April 30, 2024 | 289.77M |
| April 29, 2024 | 281.81M |
| April 26, 2024 | 307.38M |
| Date | Value |
|---|---|
| April 25, 2024 | 363.83M |
| April 24, 2024 | 401.46M |
| April 23, 2024 | 418.83M |
| April 22, 2024 | 418.83M |
| April 19, 2024 | 419.80M |
| April 18, 2024 | 450.19M |
| April 17, 2024 | 507.13M |
| April 16, 2024 | 562.13M |
| April 15, 2024 | 556.83M |
| April 12, 2024 | 597.84M |
| April 11, 2024 | 640.30M |
| April 10, 2024 | 637.88M |
| April 09, 2024 | 684.20M |
| April 08, 2024 | 646.57M |
| April 05, 2024 | 595.42M |
| April 04, 2024 | 553.45M |
| April 03, 2024 | 545.63M |
| April 02, 2024 | 547.97M |
| April 01, 2024 | 563.41M |
| March 28, 2024 | 581.75M |
| March 27, 2024 | 586.09M |
| March 26, 2024 | 576.93M |
| March 25, 2024 | 568.73M |
| March 22, 2024 | 595.74M |
| March 21, 2024 | 604.91M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-80.52M
Minimum
Jun 14 2022
935.85M
Maximum
Feb 08 2024
197.46M
Average
170.24M
Median
Jan 03 2023
Enterprise Value Benchmarks
| Editas Medicine Inc | 132.08M |
| ACADIA Pharmaceuticals Inc | 2.021B |
| Alnylam Pharmaceuticals Inc | 17.43B |
| Regeneron Pharmaceuticals Inc | 99.51B |
| Vertex Pharmaceuticals Inc | 107.33B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.05M |
| Total Expenses (Quarterly) | 28.03M |
| EPS Diluted (Quarterly) | -0.51 |
| Earnings Yield | -16.91% |